Bilaal.Raja
Company record

KROS  Keros Therapeutics, Inc.

Trailing twelve months to 2026-06-30, as filed 2026-08-03 and not restated since.
Healthcare

Scale

Market cap
$225m
Revenue TTM
$15m
Net income TTM
$-83m
Free cash flow
$-48m
Composite score
37.5
Sector rank
#2771

Valuation

P / E
—
EV / EBITDA
—
EV / sales
-2.2
FCF yield
-21.53%
Yield vs 10-yr
-42.22pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 5.28% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-553.9%
EBITDA margin
-665.2%
ROE
-31.7%
ROIC
-2,152.5%
Revenue growth
-93.5%

Insider activity, last 90 days

Net open-market
$-0.16m
Buyers
1
Sellers
7

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

In June 2024, we filed a prospectus supplement to the New Shelf Registration Statement for the issuance and sale, if any, of up to an additional $350.0 million of shares of our common stock under the ATM Sales Agreemen t. Our net income for the year ended December 31, 2025 was primarily driven by revenue related to the Takeda Agreement. In addition to the upfront payment and milestone payment, we are entitled to receive up to an aggregate of (i) $80.0 million upon the achievement of specified development milestones, (ii) $280.0 million upon the achievement of specified commercial milestones and (iii) $740.0 million upon the achievement of specified sales milestones. …Keros Therapeutics, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-03

Read the full passage →